seneste årsrapport - Sundhed.dk

Lund T, Gregersen H, Vangsted A, Marker P, Abildgaard N. Bisphosphonate-associated osteonecrosis of the jaw in
patients with multiple myeloma. Ugeskr Laeger, 2009; 5: 171(1-2):50-2.
Sondergaard TE, Pedersen PT, Andersen TL, Søe K, Lund T, Ostergaard B, Garnero P, Delaisse JM, Plesner T. A
phase II clinical trials does not show that high dose simvastatin has beneficial effect on markers of bone turnover in
multiple myeloma . Journal of Hematology & Oncology, 2009; 27(1):17-22.
Andersen TL, Sondergaard TE, Skorzynska KE, et al. A physical mechanism for coupling bone resorption and
formation in adult human bone.. American Journal of Pathology, 2009; 174 (1): 239-247.
Johnsen HE, Kjeldsen MK, Urup T, Fogd K, Pilgaard L, Boegsted M, Nyegaard M, Christiansen I, Bukh A,
Dybkaer K. Cancer stem cells and the cellular hierarchy in haematological malignancies. European Journal of
Cancer, 2009; 45 (1)1:194-201.
Johnsen HE, Knudsen LM, Mylin AK, Gimsing P, Gregersen H, Abildgaard N, Andersen NF, Plesner T, Vangsted
AJ, Mourits-Andersen T, on behalf of the Nordic Myeloma Study Group: Up-front fludarabine impairs stem cell
harvest in multiple myeloma : report from an interim analysis of the NMSG 13/03 randomized placebo controlled
phase II trial. Haematology, 2009; 1 (1): 9-13.
Björkstrand B, Klausen TW, Remes K, Gruber A, Knudsen LM, Bergmann OJ, Lenhoff S, Johnsen HE. Double
versus single high dose melphalan 200 mg/m2 and autologous stem-cell transplantation for multiple myeloma: A
region based study in 484 patients from the Nordic Area. Haematology Review/Reports, 2009; 1 (2): 62-64.
Mylin AK, Rasmussen T, Lodahl M, Dahl IM, Knudsen LM. Upregulated MCL1 mRNA expression in multiple
myeloma lacks association with survival. British Journal of Haematology, 2009; 144 (6): 961-3.
2010
Andersen TL, Søe K, Sondergaard TE, Plesner T, Delaisse JM. Myeloma cell-induced disruption of bone
remodelling compartments leads to osteolytic lesions and generation of osteoclast-myeloma hybrid cells. Br J
Haematol. 2010 Feb;148(4):551-61. Epub 2009 Nov 16
Brimnes MK, Vangsted AJ, Knudsen LM, Gimsing P, Gang AO, Johnsen HE, Svane IM. Increased level of both
CD4+FOXP3+ regulatory T cells and CD14+HLA-DR⁻ /low myeloid-derived suppressor cells and decreased level
of dendritic cells in patients with multiple myeloma. Scand J Immunol. 2010 Dec;72(6):540-7.
Engelhardt M, Udi J, Kleber M, Spencer A, Rocci A, Knop S, Bruno B, Bringhen S, Pérez-Simón JA, Zweegman S,
Driessen C, Patriarca F, Gramatzki M, Terpos E, Sezer O, Kropff M, Straka C, Johnsen HE, Waage A, Boegsted M,
Lokhorst H, Hájek R, Morgan G, Boccadoro M, Ludwig H, Cavo M, Polliack A, Sonneveld P, Einsele H, Palumbo
A. European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on
multiple myeloma. Leuk Lymphoma. 2010; 51:2006-11. Epub 2010 Aug 31
Gang AO, Arpi M, Uffe J.O. Gang, Vangsted AJ. Early infections in patients undergoing high-dose treatment with
stem cell support: a comparison of patients with non-Hodgkin lymphoma and multiple myeloma. Haematology,
2010; 15: 222-29
Gimsing P, Carlson K, Turesson I, Fayers P, Waage A, Vangsted A, Mylin A, Gluud C, Juliusson G, Gregersen H,
Hjorth-Hansen H, Nesthus I, Dahl IM, Westin J, Nielsen Jl, Knudsen LM, Ahlberg L, Hjorth M, Abildgaard N,
Andersen NF, Linder O, Wisløff F. Effect of pamidronate 30 mg versus 90 mg on physical function in patients with
newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double blind, randomised controlled trial.
Lancet Oncol. 2010; 11: 973-82
Gregersen H, Nørgaard M, Severinsen MT, Engebjerg MC, Jensen P, Sørensen HT. Monoclonal gammopathy of
undetermined significance and risk of venous thromboembolism. Eur J Haematol. 2011; 86:129-34. (Epub 2010 Dec
22)
Dansk Myelomatose Studie Gruppe side 61 Årsrapport 2011